New Cancer Drug Announced in Melbourne

A new cancer drug has been announced by Cancer Therapeutics CRC in Melbourne. CTx-294886 is to be used in conjunction with another medication, Avastin. Furthermore, a new type of scanning has been developed by the same company. It will identify protein homeostasis, a new pathway in cancer treatment.

CTx-0294886 stops tumour growth by inhibiting Focal Adhesion Kinase (FAK) and Vascular Endothelial Growth Factor Receptor 3 (VEGFR3). This with Avastin reduces angiogenesis, slowing tumor growth in breast cancer. Examination of effects in head, neck and cervical cancers is ongoing.

The company has already developed a primary anti-cancer medication, CTx-294945). Both drugs can now be used to prolong life when dancer is detected. Research was done with the assistance of Australian and international institutions.
. . . . . . . . . . . . . . . . . .